Survey
* Your assessment is very important for improving the work of artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the work of artificial intelligence, which forms the content of this project
Cellular Basis of Cancer Dr Rosemary Bass [email protected] Last session • Causes of cancer • History • Terminology used to discus cancer • Incidence Rates • Cancer Types • How cells change their nature during cancer progression Content of this lecture • Cell Growth / Cell Cycle • Tumour Growth • Cancer Progression • Benign vs Malignant Tumours • Invasion, Angiogenesis and Metastasis • Clinical Symptoms and cancer staging • Diagnosis and Treatment Cancer and Cell Growth • cancer is a genetic disease • cancer also a cellular disease • mechanisms of normal cell growth control important • understanding normal cell growth controls may provide therapeutic targets • cancer studies have also elucidated normal cell growth mechanisms Cell Cycle Mitosis G2 G1 S Phase G0 = major checkpoints Cell Cycle Checkpoints • allow progression to next phase of cell cycle • cyclins - proteins associated with each phase of cell cycle • cyclin-dependent kinases (Cdks) - activate or regulate proteins critical for each stage of cell cycle Control system co-ordinates cycle Key control proteins: Cyclin dependent kinases + cyclins (CDK or CDC) Cyclins bind CDKs - affect their ability to phosphorylate serine & threonine residues of their substrates 7 Checkpoints G2/M not completely understood Activity and levels of cyclin/CDK complexes govern these checkpoints 8 G1/S progression Rb, Myc also important De-regulation of cyclins associated with cancer Cyclins ctd. R point Cyclin B Cyclin E Nuclear D1 M Cyclin A G1 S 9 G2 M Restriction or R point Deregulation of R point decision making machinery accompanies formation of most types of cancer cells 10 Commitment to replicate chromosomes, differentiate or enter apoptosis General Controls of Cell Growth • growth Factors (GFs) eg. epidermal growth factor (EGF) eg. insulin-like growth factor I (IGF I) • hormones eg. thyroid hormones (T3, T4) • contact / density inhibition • cell anchorage and adhesion • nutrient supply (vascularisation) Tumour Growth Rate Tumour Diameter (mm) 100 10 1012 cells (patient death) 109 cells (palpable) 108 cells (visible on X-ray) 1 0.1 0 10 20 30 40 Tumour Cell Population Doublings Clonal Growth of Tumour Cells Clonal Growth of Tumour Cells (2) new sub-clones may grow How do you detect cancer? Cervical dysplasia (1) dysplastic normal http://medlib.med.utah.edu/WebPath • normal cervical squamous epithelium with dysplastic squamous epithelium Cervical dysplasia (2) normal dysplastic http://medlib.med.utah.edu/WebPath • normal / dysplastic border in cervical squamous epithelium - cells become more disorderly Cervical neoplasia Neosplastic infiltration http://medlib.med.utah.edu/WebPath • microscopic appearance of cervical neoplasia • the neoplasm is infiltrating the underlying cervical stroma Cancer Progression • cancer progression occurs in stages - dependent on cancer promoters - eg. free radicals / radiation / mutagens • sub-clones with growth advantage become: • benign tumours • malignant tumours • evidence in some tumours (eg. GI) of progression from benign to malignant Cancer Progression - Colon http://www.eurogene.org/etext/cancgen/img/Fodde2/image003.jpg Benign vs Malignant - Rapid Growth • mitoses Benign Malignant few, normal many, abnormal • nuclei normal large, irregular • necrosis/ haemorrhage never extensive Benign vs Malignant (2) - Differentiation Benign Malignant • morphology close to normal variable poor • function often retained retained, lost or abnormal products Benign vs Malignant (3) - Boundary Benign Malignant • capsule often intact • invasion absent (v. rare)frequent • metastasis never missing broken frequent Invasion • expanding tumour able to grow into tissue spaces and cavities • malignant tumours invade normal tissues normal cervix cervical carcinoma invasive process beginning http://www.ma.hw.ac.uk/~jas/researchinterests/cancerinvasion.html Discovering New Treatments for Cancer depends upon: • understanding molecular mechanisms of cancer initiation • understanding molecular mechanisms of cancer progression most cancer deaths caused by metastatic tumours • understanding of molecular mechanisms involved in metastasis important Invasion and Metastasis Steps in Metastasis • most steps are active processes • tumour cell produces enzymes / growth factors • similar to normal tissue modelling / wound healing growth factors inhibitor proteins enzymes Steps in Metastasis • cell detachment from tumour mass • invasion of surrounding tissue + invasion of blood or lymph vessel Important Proteins in Metastasis • cell Adhesion Molecules (CAMs) - lectins - cadhedrins • extracellular Matrix (ECM) proteins - collagen, fibronectin etc interact with - integrins on cell surface • all involved in normal tissue organisation / stability • interacting proteins must be overcome / digested by metastatic cancer cell Steps in Metastasis • survival of conditions in blood or lymph • most cells die after a few hours due to: - mechanical stress - lack of essential nutrients - high oxygen toxicity - destruction by immune cells Steps in Metastasis • attachment to endothelial cells in capillaries at remote site • extravasation of tumour cell through vessel wall Extravasation Important Proteins in Metastasis (2) • proteolytic enzymes - metalloproteinases - cathepsins etc • new growth stimulators - growth factors (+ receptors) - hormones • stimulators of vascularisation - more growth factors (eg. GF stimulates capillary growth) Steps in Metastasis • growth / survival as secondary tumour • stimulation of new blood supply Typical Metastatic Spread Patterns Primary Tumour • gastrointestinal carcinoma • melanoma Common Sites of Metastasis liver liver, brain, bowel • prostatic carcinoma bone • small-cell lung carcinoma • breast carcinoma brain, liver, bone marrow bone, brain, liver, adrenal, lung Angiogenesis http://www.angio.org/img/cascade_image.jpg Angiogenesis Steps 1. angiogenic growth factors (GFs) diffuse into nearby tissues 2. GFs bind to specific receptors on endothelial cells (EC) of nearby blood vessels 3. & 4. endothelial cells activated - produce enzymes that dissolve tiny holes in vessel membrane 5 - 10. ECs proliferate through holes towards tumour, form tubes and loops - become stabilised by smooth muscle Tumour Growth Rate Tumour Diameter (mm) 100 10 1012 cells (patient death) 109 cells (palpable) 108 cells (visible on X-ray) 1 0.1 TUMOUR MARKERS: aim to detect tumours as early as possible 0 10 20 30 40 Tumour Cell Population Doublings Biomarkers “A biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease. A biomarker may be used to see how well the body responds to a treatment for a disease or condition. Also called molecular marker and signature molecule” National Cancer Institute Tumour Markers Proteins↑↓ regulated in the progression of cancer Some specific for one type of cancer, others for >1 type Potential for screening/prognosis/efficacy of treatment Blood/saliva/urine vs. biopsy No routine screening in UK Classes of Tumour Marker • Oncofetal proteins - α-fetoprotein germ cell tumours primary liver cancer - CA-125 ovarian cancer • Placental Products - human chorionic gonadotrophin (hCG) - placental alkaline phosphatase choriocarcinoma teratoma ovarian cancer testicular cancer Classes of Tumour Marker • Ectopic Hormones - adrenocorticotrophic hormone (ACTH) bronchus carcinoma - calcitonin thyroid cancer • Tissue-specific Antigens - prostate-specific prostate cancer antigen (PSA) - thyroglobulin thyroid cancer Classes of Tumour Marker • Enzymes - alkaline phosphatase osteosarcoma - prostatic acid phosphatase prostate cancer - lactic dehydrogenase neroblastoma • Immunoglobulins - IgG IgA IgD IgE myeloma - Bence-Jones protein (free κ and λ chains) myeloma Cancer Treatment • surgery - principal treatment - effective local control - best before tumour spread - invasive http://www.cooperhealth.org/content/MinSurg_Cancer.asp - may involve risky procedures Cancer Treatment • Chemotherapy - body-wide drug delivery - potential to eliminate metastatic cells - damaging effects on healthy cells http://www.ucsf.edu/dpsl/chemo.html Cancer Treatment • Radiotherapy - effective local control - whole body radiotherapy possible (eg. for lymphomas) - often used to reduce tumour size prior to surgery http://www.hnsaonline.com/iort.htm Radiotherapy • External Beam - X-rays from linear accelerator - γ rays from radio-cobalt • Radioactive Implants - pellets or needles of Yttrium-90 - gives very high local dose http://www.ncrc.ac.yu/onkoeng/odelenja/images/ News Flash! Effects of Radiotherapy • both methods use ionising radiation • doses ~500000 times greater than for medical imaging • cause many double-strand breaks in DNA • cells cannot repair DNA and die • normal cells often recover more quickly than tumour cells 100% cure rare - data shown as 5-year survival Clinical Symptoms of Cancer • highly variable, vague or none • early medical attention improves prognosis • lump detectable if tumour on or near surface • general symptoms - 1 or more of: - weakness - breathlessness - weight loss - bleeding - pain (when tumour presses on nerves, internal organs or erodes bone) Clinical Symptoms of Cancer • clinical investigations: - physical examination - imaging: radiography CT (computerised tomography) ultrasound radioisotope scanning MRI (magnetic resonance imaging) lymphography - biopsy pathologist Cancer Staging (TNM) eg. lung cancer Cancer Staging - Primary Tumour Tis in situ, non-invasive T1 small, minimally invasive within primary organ site T2 larger, locally invasive within the primary organ site T3 moderate size and/or invasive, spread to adjacent lymph nodes T4 very large and/or very invasive, metastatic spread to distant organs Cancer Staging - Lymph Nodes and Metastases N0 no lymph node involvement N1 regional lymph node involvement N2 extensive regional lymph node involvement N3 distant lymph node involvement M0 no distant metastases M1 distant metastases present